Samsung Bioepis’ Adalimumab Has A Longer Life Out Of The Fridge
Samsung Bioepis’ Imraldi adalimumab biosimilar has been granted a European label update that approves the product to be stored in non-refrigerated conditions for up to 28 days.
You may also be interested in...
In the third and final part of an exclusive interview with Generics Bulletin, Samsung Bioepis CEO Christopher Hansung Ko talks about the importance of real-world data in bolstering biosimilars, as well as outlining the firm’s future pipeline.
Rolling out its Imraldi adalimumab brand across Europe is maintaining growth in Biogen’s biosimilars franchise as sales of its Benepali etanercept drug slip back.
Samsung Bioepis has entered a fifth continent by launching its Brenzys etanercept biosimilar in Brazil, as part of global expansion plans for the business.